{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-018713","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.142585+00:00","generated_at":"2026-06-06T14:51:55.648369+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML","bullets":["Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.","Phase 1 KOMET-007: 5 newly diagnosed patients on ziftomenib+7+3 all achieved CR (100%).","R/R patients on ziftomenib+ven/aza: ORR 53% (8/15); CR/CRh 56% in menin inhibitor-naïve.","No differentiation syndrome, QTc prolongation, or DLTs observed; well-tolerated.","Expects to complete KOMET-001 enrollment by mid-2024; cash runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-018713","json":"https://secwatch.observer/filing/0001193125-24-018713.json","markdown":"https://secwatch.observer/filing/0001193125-24-018713.md","text":"https://secwatch.observer/filing/0001193125-24-018713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/0001193125-24-018713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524018713/d686268d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T14:51:55.648369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}